Our Stocks to Watch today include Lux Energy Corp. (OTCBB: LUXE), Gen2Media Corp. (OTCBB: GTWO), Green Energy Live Inc. (OTCBB: GELV), Biomagnetics Diagnostics Corp. (OTC: BMGP), Wind Works Power Corp. (OTCBB: WWPW), La Jolla Pharmaceutical Co. (Nasdaq: LJPC), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS), JayHawk Energy Inc. (OTCBB: JYHW), BioTime Inc. (NYSE Amex: BTIM), RMD Entertainment Group (OTC: RMDM) and Plateau Mineral Development Inc. (OTC: PMDP).
Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover’s Digest Newsletter and Email Stock Watch Alerts.
LUX ENERGY CORPORATION (OTCBB: LUXE)
Detailed Quote: http://www.otcpicks.com/quotes/LUXE.php
Company Profile: http://www.otcpicks.com/lux-energy-corp/lux-energy-corp.htm
Lux Energy Corp. is an oil and gas production and exploration company focusing on developing oil and gas resources in
LUXE News:
December 8 - Lux Energy Corp Announces Private Funding
Lux Energy Corp. (OTCBB: LUXE), an oil and gas production and exploration company, announced an agreement for securing a longer-term private funding source(s) under terms that allow the Company to proceed with current, potentially significant opportunities.
Lux Energy will initially receive approximately $400,000.00 (USD) as the first funding tranche, which is expected to be advanced over the next several weeks by the private equity firm under agreement with the Company. The total funding amount may reach a maximum of three million U.S. dollars.
Lux Energy Corp. will secure the funds with a promissory note. Subsequently the note will be converted into common shares issued from the corporate treasury. The rate of the note conversion will be predicated on a five day average trading value basis.
Shane Broesky, President of Lux Energy Corp. comments, "The funds are arriving at a critical juncture for the Company as we embark on our Woodrush venture with Dejour Enterprises in
The necessary reporting requirements for this funding project will be filed by the corporate attorney with the regulatory agencies imminently.
GEN2MEDIA CORPORATION (OTCBB: GTWO)
Detailed Quote: www.otcpicks.com/quotes/GTWO.php
Company Profile: http://www.otcpicks.com/Newsletter/GTWO_102809.html
Gen2Media is a fully integrated technology, production and marketing company whose proprietary and patent-pending technology has earned the trust of a growing, globally diversified customer base, comprised of leading media companies, corporations, chart-topping artists, entertainment companies, advertising agencies and national brands such as The Black Eyed Peas, Mary J. Blige, Britney Spears, Justin Timberlake, Microsoft Xbox LIVE, Coca-Cola Company, Toyota, Clear Channel, and others.
GTWO News:
December 8 - Gen2Media President Mary Spio Accepts Invitation to Join
Gen2Media Corporation (OTCBB: GTWO), an innovative full service video technology and production company, announces Co-Founder and President Mary Spio has accepted an invitation to join a USA Today panel of CEOs, Presidents, Founders, and Chairmen. The panel includes over 1000 select executives from various industries including dozens from the Fortune 1000. Ms. Spio will advise on leadership trends a few times a year.
Del Jones, Corporate Management Reporter for USA Today, said he was impressed with Mary Spio’s career; from a server at McDonalds to a Digital Media Expert consulting on marketing strategies with the world’s most iconic names and brands. He said that an executive of her caliber with a client base of national brands like Coca-Cola and Microsoft definitely adds another level of expertise to the panel.
Mary Spio notes, “I am truly honored to be part of this exclusive USA Today panel. My team at Gen2Media is certainly at the cutting edge of the latest marketing trends in digital media. As the focus continues to shift from traditional to online presentations, Gen2Media is called upon to offer innovative tools that help our clients engage and interact with their customers. We offer truly impactful advertising opportunities and create amazing videos for clients over and over again.”
GREEN ENERGY LIVE INCORPORATED (OTCBB: GELV)
Detailed Quote: www.otcpicks.com/quotes/GELV.php
Company Profile: http://www.otcpicks.com/green-energy-live.htm
Green Energy Live Inc. is engaged in developing sustainable biomass-to-energy conversion technology to meet a critical need for the nation's $154 billion livestock industry. The company plans to use its proprietary gasification technology for the development of highly innovative, on-site manure-to-electricity conversion systems to enable livestock farmers and ranchers to convert their animal waste into clean, renewable energy.
GELV News:
December 8 - Skymark Research Initiates Independent Research Coverage on Green Energy Live
Skymark Research, a leading provider of small- and micro-cap independent investment research, has initiated coverage on Green Energy Live (OTCBB: GELV). Skymark Research is currently offering a complimentary trial subscription. To view the company's research, visit www.skymarkresearch.com.
December 7 - Green Energy Live Reports on Ongoing Revenue, Distribution Channel, and Customer Contacts Provided by New Subsidiary Business
Green Energy Live Inc. (OTCBB: GELV), a growing clean energy company engaged in developing sustainable biomass-to-energy conversion solutions for the U.S. livestock industry, reports that its acquisition of Comanche Livestock Exchange ("Comanche") has significantly enhanced the company's strategic and financial position. Comanche, which is now a wholly-owned subsidiary of Green Energy Live, provides ongoing revenue, livestock industry expertise, an established distribution channel and contacts with potential customers, improving Green Energy Live's ability to develop and sell manure-to-energy conversion systems.
Green Energy Live subsidiary Comanche is a leanly operated, profitable and growing business that provides ongoing revenue to support company growth and technology development. Comanche has a proven track record of success as a provider of live animal auction and livestock hauling services. In business since 1949, Comanche has an extensive network of livestock industry contacts, existing farm and ranch customers and deep industry expertise. Comanche's management is contracted to stay in place for a minimum of two years. Its established sales and management teams will provide a strategic sales channel for Green Energy Live's manure-to-energy conversion systems.
Green Energy Live plans to use its proprietary gasification technology to develop self contained, small footprint, renewable energy gasification systems to enable livestock operators to convert animal waste into clean energy. The company is focused on innovative biowaste conversion technologies that process methane gas from the manure of cows, pigs, turkeys, chickens and convert it into electricity to supply the farm's power requirements and generate revenue selling surplus power back to local utilities.
Karen Clark, President/CEO of Green Energy Live, commented: "Green Energy Live's acquisition of Comanche Livestock Exchange is a strategic move that strengthens our operational and financial foundations and positions us for sustained growth. Comanche's existing relationships and excellent reputation give us a firm foothold in the industry as well as an established distribution channel for our manure-to-energy conversion technology. We look forward to building on this synergistic relationship for the benefit of shareholders."
BIOMAGNETICS DIAGNOSTICS CORPORATION (OTC: BMGP)
Detailed Quote: http://www.otcpicks.com/quotes/BMGP.php
Company Profile: http://www.otcpicks.com/biomagnetics-diagnostics/biomagnetics-diagnostics.htm
Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company's revolutionary diagnostic systems, which are based on advanced magnetics, test for any viral or bacterial disease using any body fluid. The Company's technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test. The HTS-MTP platform is designed to detect the actual virus and viral load in body fluids and not just simply screen for the presence of viral antibodies.
BMGP News:
December 8 - Emerging Growth Research Issues Updated Report on Biomagnetics Diagnostics Corp.
Emerging Growth Research, LLP, an independent Wall Street research firm specializing in the networking and telecommunications markets, has issued an updated report on Biomagnetics Diagnostics Corp. (OTC: BMGP).
In the report, analyst Joseph Noel says he believes BMGP shares are “worth four times the current value.” To learn why, visit:
www.otcpicks.com/Newsletter/BMGP_Report_120809.pdf.
Biomagnetics Further Strengthens Balance Sheet
Company to accelerate roll out of integrated optical biosensor technology originally developed at Los Alamos National Laboratory
Biomagnetics Diagnostics Corp. (OTC: BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, announced that it has moved to further enhance its balance sheet via the acquisition of additional equity growth capital from several institutional and private investors. These funds will be used to accelerate the Company's entry into the market for integrated optical biosensors targeting HIV/AIDS, malaria, tuberculosis, cholera and other pathogen detection and disease diagnosis.
“The acquisition of this additional capital allows us increased flexibility to move into our chosen markets much more quickly. We are already working closely with one of the leading contract engineering design firms in
After the acquisition of this equity growth capital, Biomagnetics Diagnostics has only approximately 64 million outstanding shares. Management believes current working capital levels will be sufficient to bring its current set of products to market.
The Company recently announced it had finalized a "Patent License Agreement with Los Alamos National Security." Under the agreement, Biomagnetics will have access to the Triggered Optical Biosensor and Integrated Optical Biosensor System (IBOS) technology developed at Los Alamos National Laboratory.
According to the World Health Organization, some 3.2 billion people, or about half of the world's population is at risk of malaria transmission in 107 countries and territories worldwide. While there are between 350 million and 500 million new cases of malaria each year, there are very few reliable and field deployable diagnostic tools available. In the case of malaria, early detection substantially improves treatability and survivability. Field deployable Integrated Optical Biosensor System (IBOS), such as those Biomagnetics Diagnostics is planning to soon introduce, hold the promise to significantly speed the diagnostic testing process and to meaningfully lower costs and improve lives.
WIND WORKS POWER CORPORATION (OTCBB: WWPW)
Detailed Quote: http://www.otcpicks.com/quotes/WWPW.php
Company Profile: http://www.otcpicks.com/wind-works-power.htm
Wind Works' mission is to become a leading developer of wind energy projects in North America and
WWPW News:
November 30 - Wind Works Power Corp. Submits Power Contract Applications Totaling 100 MW for 8 Wind Energy Projects Under the New Feed-In Tariff Program in
Wind Works Power Corp. (OTCBB: WWPW) (Frankfurt: R5E1)(WKN: AOKE72) announces it has submitted power contract applications for 8 wind energy projects representing a total of 100 megawatts (MW) under the new Feed-in Tariff program as part of the Ontario Power Authority initial launch period.
"Wind Works has now submitted power contracts for 9 wind energy projects totaling 110MW, which includes the 10MW Clean Breeze project which was submitted earlier" commented Dr. Ingo Stuckmann, CEO and director of Wind Works. "We look forward to being awarded power contracts, as our stated objective is to commence construction on a minimum of 20MW of wind energy projects in
Power contract applications have now been submitted for the following
1.
2.
3.
4. Skyway 126 Wind Park: 70% interest in a 10 MW project located in Grey-Highlands Township, Ontario, Canada on the north east side of the Garafraxa Plateau, the highest land mass in Ontario;
5. Polar Bear Wind Park: 50% interest (with an option to increase to 100%) in a 20MW project located in
6. Pleasant Bay Wind Park: 50% interest (with an option to increase to 100%) in a 20MW project located in an area just north of the shores of Lake Ontario that has one of the best wind regimes in Ontario;
7.
8.
9.
The Feed-in Tariff (FIT) contract program is part of the new Green Energy Act in
About Zero Emission People
The vision of Zero Emission People is to provide the opportunity for anyone to invest early in the development of renewable wind energy projects. As an example, as little as a $10,000 investment in a wind park blows away a person's carbon footprint. We believe in making sound, environmentally conscious investments that are good for all shareholders, people and our planet.
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ: LJPC)
"Up 63.23% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LJPC.php
La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions.
LJPC News:
December 8 - Emerging Stock Report Initiates Independent Research Coverage on La Jolla Pharmaceutical Company
Emerging Stock Report, a leading provider of sector specific independent investment research, has initiated coverage on La Jolla Pharmaceutical Company (Nasdaq: LJPC). Emerging Stock Report is currently offering a complimentary trial subscription to the investment community. To view the report in its entirety visit www.emergingstockreport.com.
December 7 - Adamis Pharmaceuticals Announces Signing of Definitive Merger Agreement
Adamis Pharmaceuticals Corporation (OTCBB: ADMP), announced that it has entered into a definitive merger agreement providing for the acquisition of La Jolla Pharmaceutical Company (Nasdaq: LJPC) by Adamis. The transaction was unanimously approved by the boards of directors of both companies and is anticipated to close by the end of the first calendar quarter of 2010 or as soon thereafter as possible. Completion of the transaction is subject to a number of customary closing conditions, including the effectiveness of a registration statement to be filed with the Securities and Exchange Commission relating to the transaction, and approval of Adamis’ and
Adamis’ chief executive officer, Dr. Dennis J. Carlo, will become the chief executive officer of the combined company. Dr. Carlo is a veteran of the pharmaceutical and biotechnology industry. He previously served as CEO of publicly-traded Immune Response Corporation, Vice President of Research and Development and Therapeutic manufacturing of Hybritech Inc. prior to its acquisition by Eli Lilly & Co., and Director of Bacterial Vaccines and Immunology at Merck & Company. Dr. Carlo stated, “This merger is a strategic move to raise additional capital for the purpose of increasing the marketing and sales efforts of our Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe) product that we recently launched. In addition, we believe that
Dr. Deirdre Y. Gillespie, La Jolla’s CEO, stated, “The merger of La Jolla and Adamis will create a new specialty pharmaceutical company focused on the development and commercialization of therapeutic products for a variety of viral diseases, including hepatitis and influenza. We like the fact that in addition to the prefilled epinephrine syringe, Adamis has a pipeline including products for allergic rhinitis, asthma, and chronic obstructive pulmonary disease. We think Adamis is very unique in that it already has a product on the market and is expected to be profitable in the near-term.”
At the effective time of the merger, each outstanding share of Adamis common stock will be converted into the right to receive one (post-reverse stock split) share of
The percentage ownership of shares after the merger that will be held by persons who were La Jolla stockholders and Adamis stockholders, respectively, will depend on many factors, including without limitation the reverse stock split ratio for the
The merger agreement contains customary non-solicitation provisions restricting
ABOUT ADAMIS PHARMACEUTICALS
Adamis Pharmaceuticals has two wholly owned subsidiaries, Adamis Laboratories and Adamis Viral Therapies. Adamis Labs expects to launch a series of niche prescription products in the allergy and respiratory therapeutic area, beginning with the Epinephrine Injection USP 1:1000 (0.3mg Pre-Filled Single Dose Syringe) product. Adamis Viral Therapies is focused on the development of patented, proprietary vaccine technology that Adamis believes may have the capability of generating a broad-based immunity for both B Cells (antibody) and T cells (cell mediated immunity). If successful, Adamis’ technology could lead to the development of new vaccines against a multitude of viruses, including chronic hepatitis and all forms of influenza. Shoreline Pacific has acted in an advisory role to Adamis during this transaction.
SUNESIS PHARMACEUTICALS INCORPORATED (NASDAQ: SNSS)
"Up 34.02% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/SNSS.php
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer.
SNSS News:
December 7 - Sunesis Presents Positive Phase 2 Clinical Data of Voreloxin in Acute Myeloid Leukemia at the American Society of Hematology 2009 Annual Meeting
Conference Call Scheduled for December 8 at 2:00 PM EST to Discuss ASH Data Presentations
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced positive data from two Phase 2 clinical trials of the Company's lead drug candidate, voreloxin. The results highlight voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy in patients with difficult to treat acute myeloid leukemia (AML). The trial results were presented at the 51st American Society Hematology (ASH) Annual Meeting in
"These results provide us with the efficacy and safety data to move voreloxin forward into pivotal testing," said Steven Ketchum, Ph.D., Senior Vice President of Research and Development at Sunesis. "Trial results show that the high rates of remission observed in both trials have translated into durable effects with meaningful preliminary overall survival results. With an anticipated median survival of three and a half to six months on currently available therapies, primary refractory and first relapse AML patients are particularly in desperate need of more effective treatment options. We look forward to discussing these data with the FDA in our End-of-Phase 2 meeting scheduled for the first quarter of 2010."
Phase 1b/2 Clinical Trial of Voreloxin in Combination with Cytarabine in Relapsed/Refractory (Abstract No. 645)
In an oral presentation, Jeffrey Lancet, M.D., Associate Member, Section Chief - Leukemia, Department of Hematologic Malignancies, at the H. Lee Moffitt Cancer Center & Research Institute and a clinical trial investigator, presented data from a Phase 1b/2 clinical trial testing voreloxin in combination with cytarabine, a widely used chemotherapy, in patients with relapsed or refractory AML. The trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered in combination with cytarabine given either as continuous infusion or as a two hour IV infusion. To date, 66 patients have been treated in the expansion Phase 2 populations of the trial, which includes primary refractory and first relapse AML patients. Of these, 64 patients were evaluable for efficacy outcomes.
* Among evaluable first relapse (n=36) and primary refractory patients (n=28), preliminary median overall survival is 7.8 months and the remission rate is 31% (complete remission [CR] 27%, complete remission without full platelet recovery [CRp] 2% and complete remission with incomplete recovery [CRi] 2%). Historical median overall survival data in primary refractory and first relapse patients on currently available chemotherapies range from 3.4 to 5.9 months.
* Voreloxin in combination with either bolus or continuous infusion cytarabine was generally well-tolerated. Infection-related toxicities were the most common Grade 3 or higher non-hematologic adverse events. In addition, Grade 3 or higher oral mucositis was observed.
* All-cause mortality among these patients was 1% at 30 days and 8% at 60 days.
* A recommended pivotal dose-regimen of voreloxin used in combination with cytarabine has been identified.
"Voreloxin has induced remissions in difficult to treat relapsed, primary refractory and relapsed/refractory AML patients," said Dr. Lancet. "Voreloxin used in combination with cytarabine has demonstrated meaningful anti-leukemic activity with an acceptable tolerability profile in these difficult-to-treat patients."
Phase 2 Clinical Trial of Single Agent Voreloxin in Newly Diagnosed Elderly AML (REVEAL-1 Trial) (Abstract No. 1037)
In a poster presentation, investigators presented data from the fully enrolled REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose optimization trial of single agent voreloxin in previously untreated, elderly AML patients who are unlikely to benefit from standard induction chemotherapy. 113 AML patients have been treated in the trial, all of whom had at least one additional adverse risk factor at enrollment, including intermediate or unfavorable cytogenetics in the majority of patients. Median age for patients in the trial was 74 years. The trial includes three dosing schedules: Schedule A, once weekly for three weeks (n=29); Schedule B, once weekly for two weeks (n=35); and Schedule C, on days one and four at either 72 mg/m2 (n=29) or 90 mg/m2 (n=20).
* Median survival was 8.7 months in Schedule A; 5.8 months in Schedule B; and 7.3 months (preliminary) in Schedule C (72 mg/m2 on days one and four).
* Median duration of remission was 10.7 months and one year survival was 38% for Schedule A. For the other schedules, median duration of remission has not been reached and one year survival is too early to evaluate.
* Patients age 75 or older (N=49) with at least 1 additional risk factor at diagnosis, a population identified by the National Comprehensive Cancer Network (2010) AML Guidelines as having poor outcome to standard treatment, experienced a CR rate of 30% and a 30-day all-cause mortality of 5%. Survival in these patients was too early to evaluate.
* Based on trial results, Schedule C has been determined to be the recommended pivotal dose regimen. For Schedule C, response rates (CR and CRp) are 38%; 30- and 60-day all-cause mortality are 7% and 17% with improved tolerability over Schedule A.
"Voreloxin has demonstrated a unique combination of anti-leukemic activity and tolerability, important for patients who are unlikely to benefit from standard induction therapy," said Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, and an investigator in the Phase 2 clinical trial. "Particularly encouraging are the durable response, tolerability and promising survival results in the Schedule C group. I look forward to seeing further data from this trial as it matures, particularly voreloxin's durability and overall survival in Schedule C."
Conference Call and Slide Presentation Information
The company will host a conference call and webcast slide presentation December 8, 2009 at 2:00 PM EST to discuss the Company's new clinical data. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team to review the updated data from the Company's Phase 2 studies of voreloxin. The call can be accessed by dialing 888-726-2443 (
ABOUT VORELOXIN
Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.
ABOUT ACUTE MYELOID LEUKEMIA
AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the
JAYHAWK ENERGY INCORPORATED (OTCBB: JYHW)
"Up 18.57% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/JYHW.php
JayHawk Energy, Inc., a development stage company, engages in the exploration, acquisition, development, production, and sale of natural gas, crude oil, and natural gas liquids primarily from conventional reservoirs in
JYHW News:
September 21 - JayHawk Announces Discovery of Proven & Dependable Production Capabilities and Extension of $800,000 Debenture
JayHawk Energy, Inc. (OTCBB: JYHW) (“JayHawk”) provides an operational update regarding its Southeast Kansas oil and gas projects namely the: (1) Uniontown project, located in Bourbon County, Kansas; (2) Girard project, Crawford County, Kansas; and (3) several other shallow oil opportunities within our existing acreage that can exploited via Enhanced Oil Recovery (EOR) (collectively the “Projects”). JayHawk previously entered into a joint venture with DK True Energy Development Limited (“True Energy”) and its affiliates whereby True Energy is to be the operator and will earn up to an 85% equity position in the Projects via an investment of $1.8 MM over a 3 year period.
ABOUT THE UNIONTOWN AND GIRARD PROJECTS
The Uniontown and Girard projects consist of mineral leases covering approximately 45,000 gross acres in Bourbon and
Shallow Oil Resources
Concurrent to completing its geological and reservoir due diligence on the “Home Run” Kansas CBM project, True Energy has further delineated significant oil reservoirs that have been over-looked or were prematurely shut-in during the 1980s and now provide an opportunity to restart that project as much of the infrastructure is in place.
The Home Run project areas are located on the
The eastern side of the
Following its analysis of the region, True Energy now has an increased understanding of the characteristics of the project acreage and has demonstrated there are several reservoirs present. All of the reservoirs discovered target the Upper and
JayHawk CEO Lindsay Gorrill states “we are extremely pleased by this outcome, these developments provide a significant increase in the resource base of JayHawk that was not expected during our initial due diligence phase in
The company has also successfully negotiated the extension, to July 31, 2010, a $800,000 debenture payable to Starshell Consultants.
BIOTIME INCORPORATED (OTCBB: BTIM)
"Up 19.86% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BTIM.php
BioTime, headquartered in
BTIM News:
December 4 - BioTime CEO Dr. Michael West to Ring The Opening Bell at the
BioTime, Inc. (NYSE Amex: BTIM) Chief Executive Officer Michael D. West, Ph.D. will ring The Opening Bell at the New York Stock Exchange at 9:30 a.m. Eastern on Tuesday, December 8, 2009. Executives and guests of BioTime will also be at the ceremony to celebrate the company's recent listing on the NYSE Amex. Trading of BioTime’s common shares and warrants commenced on the NYSE Amex on Friday, October 30, 2009 under the ticker symbols “BTIM” for the common shares and “BTIM.WS” for the warrants.
The bell ringing will be webcast live on www.nyse.com and live to the jumbo screen on the W Hotel in
RMD ENTERTAINMENT GROUP (OTC: RMDM)
"Up 20.00% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/RMDM.php
RMD Entertainment Group, an entertainment company, primarily focuses on the development and marketing of hip-hop music in the
RMDM News:
December 8 - United Liquor
RMD Entertainment's (OTC: RMDM) subsidiary United Liquor Alliance (www.united-liquor.com) seeks strategic partnership and vendor relationship Green World Path, Inc.
Green World Path has focused the past 35 years promoting a new kind of sustainable agriculture in which mankind and the environment are as important as profits. The result has been the development of a unique line of products that combine ingredients like botanicals, ocean-harvested fish and sea plants, fermented complex sugars, organic carbons, clean offal, bacteria, enzymes, and minerals with special chelators and catalysts (utilizing the latest in biotechnology). These advanced formulations offer dramatic examples of adding value to natural raw materials, which become high-tech agricultural products commanding premium prices. Green World Path, Inc. manufactures over 45 innovative products for sustainable agriculture and other green industries.
ULA talks with Green World Path centered around 3 major issues focusing on continued growth.
The first is the byproduct created by the use of molasses. ULA uses molasses in the production of rum, what is left is a thick syrup which most companies traditionally pay to dispose of. ULA plans to turn the by-product into a profit center verses an added expense. Green World Path would be able to utilize the by-product to create environmentally friendly products.
The second issue discussed was the use of herbal healthy remedies which help alleviate the side effects associated with hangovers. ULA plans to market a follow up to the bottle water with a natural hangover solution which can be bottled with water and sold at high margins with the same distributors for alcohol.
The third issue discussed was utilizing environmentally safe containers. "The containers we utilize for our products are one of the largest expenses. We want to work with companies like Green World Path to not only find lower costing products but more environmentally safe" said Shane Cooper of ULA.
PLATEAU MINERAL DEVELOPMENT INCORPORATED (OTC: PMDP)
"Up 11.11% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/PMDP.php
Plateau Mineral Development, Inc. specializes in the exploration and development of energy sources. Its partner, Plateau Mineral Development LLC, has been in existence for over five years with successful new wells and rework wells selling both gas and oil.
PMDP News:
December 8 - Plateau Mineral Development, Inc. Announces Appointment of William Strange as President
Plateau Mineral Development, Inc. (OTC: PMDP), along with its partner, Plateau Mineral Development LLC, announced today that the company has appointed William Strange as President, effective immediately.
William "Bill" Strange has thirty years of experience in the refineries, petro-chemical, and oil field. He is well-versed in bio-remediation, pipefitting and fabrication, process troubleshooting and construction management. Mr. Strange was employed for more than ten years by Raines Contractors in
William Strange, President elect for Plateau, states, "I am honored to have been chosen for this position and am eager to get started. I believe that a great deal of potential lies within Plateau, and I'm looking forward to taking part in the growth of the company."
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org/.
Disclosure: OTCPicks.com has received three thousand dollars from a third party (Heritage First Capital) for LUXE advertising and promotional services. OTCPicks.com has been compensated two thousand dollars by a third party (Blue Wave Advisors) for a one week GTWO advertising and promotional program. OTCPicks.com has been compensated ten thousand dollars by a third party (Emerging Market Consultants) for GTWO advertising and promotional services. OTCPicks.com has been compensated four thousand dollars by a third party for a one-week GELV advertising and promotional program. OTCPicks.com has been previously compensated seven thousand five hundred dollars by a third party for BMGP advertising and promotional services. OTCPicks.com has been compensated twelve thousand five hundred dollars by a third party for BMGP advertising and promotional services. OTCPicks has been compensated two thousand five hundred dollars from a non-controlling third party (BlueWave Advisors) for WWPW advertising and promotional services. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. OTCPicks.com is a website partially owned by BlueWave Advisors, LLC, a financial public relations firm. BlueWave Advisors, LLC, its principal and/or its affiliates will hold positions in the company profiled and may buy or sell securities at any time without notice.
